新規診断転移性非小細胞肺癌に対するペンブロリズマブ（+）ベラヒアルロニダーゼアルファ（MK-3475A）の臨床試験（MK-3475A-F84）

基本情報

NCT ID

NCT06698042

ステータス

実施中（募集終了）

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

67

治験依頼者名

Merck Sharp & Dohme LLC

概要

Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to learn what happens to pembrolizumab in a person's body over time when it is given as an IV infusion or SC injection.

対象疾患

介入

依頼者（Sponsor）

実施施設 (13)